Bill H.676 aims to ensure the continued availability of animal-derived thyroid medications, specifically desiccated thyroid extract, for Vermonters who find these medications more effective or better tolerated than synthetic alternatives. The bill directs the Office of Professional Regulation to collaborate with the Department of Financial Regulation, healthcare professionals, health insurers, patients with thyroid-related disorders, and other stakeholders to explore all options for maintaining access to these medications. The Office is tasked with implementing feasible options that do not require legislative action.

Additionally, the bill mandates that by January 15, 2027, the Office of Professional Regulation must report its findings and recommendations to the House Committee on Health Care and the Senate Committee on Health and Welfare, detailing the options that have been implemented and any that may require further legislative action. The act is set to take effect upon passage.